Literature DB >> 25096712

Giant cell polymyositis associated with myasthenia gravis and thymoma.

Jie Lin1, Jun Lu1, Chongbo Zhao1, Kai Qiao2, Wenhua Zhu1, Dongyue Yue1, Sushan Luo1, Yin Wang3, Wentao Fang4, Jiahong Lu1.   

Abstract

We report a case of a 40-year-old woman who developed generalized muscle weakness over a period of 2 months. Physical examination revealed palpable masses in her arms and hands. Serum creatine kinase levels were elevated. Electromyography showed myopathic changes and 3 Hz repetitive nerve stimulation revealed a decremental pattern on repetitive nerve stimulation. Muscle MRI demonstrated increased signal intensity in the biceps brachii on T1-weighted images. Chest CT scan showed a mediastinal mass suggestive of thymoma. Muscle biopsy revealed giant cell polymyositis. The patient was treated with cholinesterase inhibitors and corticosteroids with improvement of strength, and subsequently underwent thymectomy followed by radiotherapy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Giant cell polymyositis; Muscle MRI; Myasthenia gravis; Thymoma

Mesh:

Year:  2014        PMID: 25096712     DOI: 10.1016/j.jocn.2014.04.027

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

Review 1.  Giant cell myositis associated with concurrent myasthenia gravis: a case-based review of the literature.

Authors:  Frank A Scangarello; Luisa Angel-Buitrago; Melanie Lang-Orsini; Alexander Geevarghese; Knarik Arkun; Oscar Soto; Mithila Vullaganti; Robert Kalish
Journal:  Clin Rheumatol       Date:  2021-02-25       Impact factor: 2.980

2.  Reversible spontaneous EMG activity during myasthenic crisis: Two case reports.

Authors:  Theocharis Tsironis; Santiago Catania
Journal:  eNeurologicalSci       Date:  2018-11-20

3.  A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.

Authors:  M I Stefanou; L Komorowski; S Kade; A Bornemann; U Ziemann; M Synofzik
Journal:  BMC Neurol       Date:  2016-09-13       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.